Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Lynparza | Olaparib | Ovarian Cancer | Do not reimburse | Complete | ||
Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | ||
Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete | ||
Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | |||
Myrbetriq | Mirabegron | Overactive bladder | List with criteria/condition | Complete | ||
Mictoryl | Propiverine hydrochloride | Overactive bladder (OAB) | Reimburse with clinical criteria and/or conditions | Complete | ||
Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | ||
Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | ||
Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | ||
Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn |